DC ap­peals court quash­es Nos­trum's suit against FDA, ex­plain­ing CRLs are not fi­nal re­jec­tions

A Mis­souri-based phar­ma com­pa­ny, once at the cen­ter of a Shkre­li-es­que gener­ic drug pric­ing scan­dal, just lost its chance to chal­lenge the FDA’s com­plete re­sponse …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER